Skip to main content
An official website of the United States government


Placeholder slot

Tislelizumab-jsgr works by keeping cancer cells from suppressing the immune system. It binds to the protein PD-1 on the surface of immune cells called T cells, allowing the immune system to recognize and kill the cancer cells. Tislelizumab-jsgr is a type of immunotherapy (immune checkpoint inhibitor) and a type of targeted therapy (monoclonal antibody).

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Tislelizumab-jsgr is approved to treat:

Tislelizumab-jsgr is also being studied in the treatment of other types of cancer.

More About Tislelizumab-jsgr

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Tislelizumab-jsgr - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: